Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.
Yi Ning
Novo Nordisk (China) Pharmaceuticals
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
31
SSRN CITATIONS
0
CROSSREF CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Prevalence of Obesity and Associated Complications in China: A Nationwide, Cross-Sectional, Observational, Real-World Study in 15.8 Million Adults
Number of pages: 40
Posted: 14 Dec 2022
Kang Chen
,
Zewei Shen
,
Weijun Gu
,
Zhaohui Lyu
,
Xuan Qi
,
Yiming Mu
and Yi Ning
Government of the People's Republic of China - Department of Endocrinology, Novo Nordisk (China) Pharmaceuticals, Government of the People's Republic of China - Department of Endocrinology, Government of the People's Republic of China - Department of Endocrinology, Novo Nordisk (China) Pharmaceuticals, Government of the People's Republic of China - Department of Endocrinology and Novo Nordisk (China) Pharmaceuticals
Downloads
31
(727,967)
View PDF
Download
Abstract:
Obesity, Overweight, China, Prevalence, weight-related complications
Feedback
